Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Journal of Biological Science and Education Journal of Biological Science and Education
Henik Anjayati
Institut Teknologi Bandung
Biochemistry, Genetics & Molecular Biology Education Immunology & microbiology Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Lentiviral shRNA Construction in Gene Therapy for Knock Down CYPIA1, and YWHAZ gene in Lung Cancer Henik Anjayati
Journal of Biological Science and Education Vol 3, No 1 (2021): June
Publisher : Journal of Biological Science and Education

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31327/jbse.v3i1.1436

Abstract

Lung cancer is a disease that is in the top 10 causes of death globally. It is caused by CYP1A1 and YWHAZ genes expressed in the lungs. One of the solutions offered for lung cancer sufferers is gene therapy. Gene therapy for lung cancer is focused on the knock-down of expressed CYP1A1 and YWHAZ genes. It can be using shRNA transfected into lung cells by lentivirus. The lentivirus envelope is modified using glycoprotein filovirus, one of which is ebolavirus. Lentivirus pseudotyping can recognize certain cells. Especially, Ebolavirus can recognize lung cells. The lentiviral gene is designed to carry the gene of interest (shRNA) but no the infectious gene. The shRNA gene transfused into lung cancer cells will recognize and complement the specific target mRNA sites of the CYP1A1 and YWHAZ genes. After that, shRNA will cut the mRNA which should be expressed into a cancer protein. Unexpressed mRNA into protein causes cancer cell growth inhibited. Thus, this gene therapy solution is expected to be able to reduce the rate of death caused by lung cancer. Keywords: Lung cancer, CYP1A1 and YWHAZ genes, gene therapy, lentiviral, shRNA
Lentiviral shRNA Construction in Gene Therapy for Knock Down CYPIA1, and YWHAZ gene in Lung Cancer Henik Anjayati
Journal of Biological Science and Education Vol 3, No 1 (2021): June
Publisher : Journal of Biological Science and Education

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (782.935 KB) | DOI: 10.31327/jbse.v3i1.1436

Abstract

Lung cancer is a disease that is in the top 10 causes of death globally. It is caused by CYP1A1 and YWHAZ genes expressed in the lungs. One of the solutions offered for lung cancer sufferers is gene therapy. Gene therapy for lung cancer is focused on the knock-down of expressed CYP1A1 and YWHAZ genes. It can be using shRNA transfected into lung cells by lentivirus. The lentivirus envelope is modified using glycoprotein filovirus, one of which is ebolavirus. Lentivirus pseudotyping can recognize certain cells. Especially, Ebolavirus can recognize lung cells. The lentiviral gene is designed to carry the gene of interest (shRNA) but no the infectious gene. The shRNA gene transfused into lung cancer cells will recognize and complement the specific target mRNA sites of the CYP1A1 and YWHAZ genes. After that, shRNA will cut the mRNA which should be expressed into a cancer protein. Unexpressed mRNA into protein causes cancer cell growth inhibited. Thus, this gene therapy solution is expected to be able to reduce the rate of death caused by lung cancer. Keywords: Lung cancer, CYP1A1 and YWHAZ genes, gene therapy, lentiviral, shRNA
Co-Authors